Compare BGSI & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BGSI | TMDX |
|---|---|---|
| Founded | 1990 | 1998 |
| Country | Canada | United States |
| Employees | 13449 | N/A |
| Industry | | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.8B |
| IPO Year | N/A | 2019 |
| Metric | BGSI | TMDX |
|---|---|---|
| Price | $120.14 | $97.89 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 9 |
| Target Price | ★ $157.00 | $148.22 |
| AVG Volume (30 Days) | 27.9K | ★ 801.7K |
| Earning Date | 05-13-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.38% | N/A |
| EPS Growth | N/A | ★ 382.18 |
| EPS | N/A | ★ 4.87 |
| Revenue | N/A | ★ $605,494,000.00 |
| Revenue This Year | $35.07 | $24.25 |
| Revenue Next Year | $8.01 | $18.75 |
| P/E Ratio | $231.07 | ★ $20.18 |
| Revenue Growth | N/A | ★ 37.13 |
| 52 Week Low | $115.40 | $89.10 |
| 52 Week High | $183.10 | $156.00 |
| Indicator | BGSI | TMDX |
|---|---|---|
| Relative Strength Index (RSI) | 36.59 | 35.56 |
| Support Level | $115.40 | $97.66 |
| Resistance Level | $131.30 | $120.60 |
| Average True Range (ATR) | 4.35 | 5.37 |
| MACD | 1.27 | -0.57 |
| Stochastic Oscillator | 19.23 | 5.27 |
Boyd Group Services Inc is engaged in operating non-franchised collision repair centers in North America. The Company's primary line of business is automotive collision and glass repair and related services, with the majority of revenues relating to this group of similar services. This line of business operates in Canada and the U.S. and both regions exhibit similar long-term economic characteristics. he Company is also a retail auto glass operator in the United States, under the trade names Gerber Collision & Glass, Glass America, Auto Glass Service, Auto Glass Authority. The company has majority of its sales from USA.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.